Laboratory of Human Genetics of Neurological Disorders, IRCCS San Raffaele Scientific Institute, Institute of Experimental Neurology, 20132 Milan, Italy.
Department of Toxicogenomics, Maastricht University, 6229 ER Maastricht, The Netherlands.
Int J Mol Sci. 2024 Jun 30;25(13):7248. doi: 10.3390/ijms25137248.
Small-Fiber Neuropathy (SFN) is a disorder of the peripheral nervous system, characterised by neuropathic pain; approximately 11% of cases are linked to variants in Voltage-Gated Sodium Channels (VGSCs). This study aims to broaden the genetic knowledge on painful SFN by applying Whole-Exome Sequencing (WES) in Early-Onset (EO) cases. A total of 88 patients from Italy (n = 52) and the Netherlands (n = 36), with a disease onset at age ≤ 45 years old and a Pain Numerical Rating Score ≥ 4, were recruited. After variant filtering and classification, WES analysis identified 142 potentially causative variants in 93 genes; 8 are Pathogenic, 15 are Likely Pathogenic, and 119 are Variants of Uncertain Significance. Notably, an enrichment of variants in transient receptor potential genes was observed, suggesting their role in pain modulation alongside VGSCs. A pathway analysis performed by comparing EO cases with 40 Italian healthy controls found enriched mutated genes in the "Nicotinic acetylcholine receptor signaling pathway". Targeting this pathway with non-opioid drugs could offer novel therapeutic avenues for painful SFN. Additionally, with this study we demonstrated that employing a gene panel of reported mutated genes could serve as an initial screening tool for SFN in genetic studies, enhancing clinical diagnostics.
小纤维神经病(SFN)是一种周围神经系统疾病,其特征为神经性疼痛;大约有 11%的病例与电压门控钠离子通道(VGSCs)的变异有关。本研究旨在通过对早发性(EO)病例进行全外显子组测序(WES),拓宽对疼痛性 SFN 的遗传认识。共招募了来自意大利(n=52)和荷兰(n=36)的 88 名患者,发病年龄≤45 岁,疼痛数字评分≥4。经过变异过滤和分类,WES 分析在 93 个基因中鉴定出 142 个潜在致病变异;其中 8 个是致病性的,15 个是可能致病性的,119 个是意义不明的变异。值得注意的是,观察到瞬时受体电位基因的变异富集,提示它们与 VGSCs 一起在疼痛调节中发挥作用。通过将 EO 病例与 40 名意大利健康对照进行比较进行的通路分析发现,“烟碱型乙酰胆碱受体信号通路”中富集了突变基因。用非阿片类药物靶向该通路可能为疼痛性 SFN 提供新的治疗途径。此外,通过本研究我们证明,在遗传研究中使用报告的突变基因基因panel 可以作为 SFN 的初始筛选工具,增强临床诊断。